BD Diagnostics Gets FDA Clearance for Second BD Max Staph Assay | GenomeWeb

NEW YORK (GenomeWeb News) — BD Diagnostics, a segment of Becton Dickinson, said today that it has received US Food and Drug Administration clearance to market its BD Max MRSA XT assay for use on the BD Max system.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.